Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA

Wasatch Advisors LP decreased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 51.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,649 shares of the company’s stock after selling 134,215 shares during the quarter. Wasatch Advisors LP owned about 0.09% of Intellia Therapeutics worth $2,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Intellia Therapeutics by 38.0% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 220,523 shares of the company’s stock worth $3,731,000 after acquiring an additional 60,720 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Intellia Therapeutics in the first quarter valued at $404,000. Avidity Partners Management LP bought a new stake in shares of Intellia Therapeutics during the 1st quarter valued at $962,000. Wellington Grp LLC lifted its holdings in Intellia Therapeutics by 50.9% during the 1st quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock worth $594,000 after purchasing an additional 15,620 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent analyst reports. The Goldman Sachs Group lifted their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th. Chardan Capital raised their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Morgan Stanley boosted their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Robert W. Baird upped their target price on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, April 27th. Finally, Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $21.15.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $12.09 on Thursday. The firm’s 50 day simple moving average is $13.57 and its 200 day simple moving average is $13.44. The company has a market capitalization of $1.69 billion, a P/E ratio of -3.60 and a beta of 1.81. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting analysts’ consensus estimates of ($0.80). The business had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business’s quarterly revenue was down 46.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.98) EPS. On average, equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Edward J. Dulac III sold 4,677 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at approximately $1,122,347.08. This represents a 3.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.50% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.